Detection of Acute Renal Failure Using Hospital Coding Data

Overview

AKI is a rapid and usually reversible impairment of kidney function that is life-threatening in the short term well described by the "Kidney Disease: Improving Global Outcomes – KDIGO" classification of 2012. Whatever etiology of acute renal failure, drug iatrogeny still has its place. Hospital data from the information systems medicalization program (PMSI) can be used for epidemiological research. No study has yet been performed on these data to assess drug-related AKI. However, it should be remembered that these databases were not originally designed for research purposes but for reimbursement of care. Therefore, before conducting a large-scale study, it remains important to determine the validity and representativeness of the codes used for coding the studied events. The objective of this project is therefore to validate the use of hospital coding to identify AKI.

Full Title of Study: “Acute Kidney Injury and Drug-related Acute Kidney Injury : Use of Hospital Coding Data for Their Identification”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2023

Detailed Description

Acute kidney injury (AKI) is a rapid and usually reversible impairment of kidney function that is life-threatening in the short term; the grades of which are defined by the KDIGO classification of 2012. Whatever etiology of acute renal failure, drug iatrogeny still has its place. Data literature indicate that AKI affects more than one in five adults worldwide while hospitalized, with an associated mortality rate above 20%. It constitutes a non-negligible part of hospitalizations when it is acquired in the community, and also causes prolongations of hospitalizations, and therefore an increase in the cost for the hospital. Hospital data from the information systems medicalization program (PMSI) is a device that is part of the reform of the French health system with the aim of reducing inequalities in resources between health establishments. Since 2007, it has been possible to link all discharge summaries for one patient. The diagnoses identified during hospitalization are coded according to the 10th edition of the International Classification of Diseases (ICD-10). The data from PMSI coding can be used for epidemiological research. The majority of studies were related to patients with chronic kidney disease, especially dialysis patients. No study has yet been performed on these data to assess drug-related AKI. However, it should be remembered that these databases were not originally designed for research purposes but for reimbursement of care. Therefore, before conducting a large-scale study, it remains important to determine the validity and representativeness of the codes used for coding the events to be studied.

Clinical Trial Outcome Measures

Primary Measures

  • identification of AKIs by codes in the PMSI database
    • Time Frame: two years
  • identification of drug-induced AKIs by codes in the PMSI database
    • Time Frame: two years

Secondary Measures

  • Variation of performance of the codes according to the characteristics of the AKI
    • Time Frame: two years
  • Variation of performance of the codes according to KDIGO grade
    • Time Frame: two years
  • Variation of performance of the codes according to hospitalization service
    • Time Frame: two years
  • Identification of the type of drugs involved in drug-induced AKI
    • Time Frame: two years
  • incidence of drug-induced AKI
    • Time Frame: two years
    • incidence of drug-induced AKI (community-based and hospital-induced AKI (AKI-AH))
  • Identification of AKI Risk factors
    • Time Frame: two years

Participating in This Clinical Trial

Inclusion Criteria

  • Patients over > = 18 years old – Patients hospitalized at the CHU Amiens Picardie during 6 months – patients for which at least two plasma creatinine measurements were taken during the hospitalization Exclusion Criteria:

  • Patients under <18 years old – Patients on dialysis for chronic renal failure – Hospitalization for a kidney transplant – Postpartum AKI

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Centre Hospitalier Universitaire, Amiens
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Sophie LIABEUF, Pr, 03 22 08 79 95, Liabeuf.sophie@chu-amiens.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.